Abstracts tagged "NT-proBNP"

Abstract Number: 736 • 2017 ACR/ARHP Annual Meeting
N-Terminal Pro-Brain Natriuretic Peptide Is Disproportionately Elevated in Scleroderma Associated Pulmonary Arterial Hypertension Compared to Idiopathic Pulmonary Arterial Hypertension
Alexander Hannan¹, Raed Dweik², Kristin B. Highland³, Gustavo Heresi⁴, Adriano Tonelli⁵, William Messner⁶ and Soumya Chatterjee^1,7, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Respiratory Institute, Cleveland Clinic, Cleveland, OH, ³Rheumatology.org, Cleveland Clinic, Cleveland, OH, ⁴Respiratory Institute - Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ⁵Pulmonary Medicine - Respiratory Institute, Cleveland Clinic, Cleveland, OH, ⁶Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁷Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: N-Terminal pro-brain natriuretic peptide (NT-proBNP) level tends to correlate with myocardial wall stress and/or myocardial damage (fibrosis). Hence, it has been promoted as a…
Abstract Number: 843 • 2015 ACR/ARHP Annual Meeting
Natriuretic Peptide Predicts Mortality in Systemic Sclerosis
Christophe Meune¹, Andras Komocsi², Serena Vettori³, Eric Hachulla⁴, Jerome Avouac⁵, Nicolas Hunzelmann⁶, Jorg HW. Distler⁷ and Yannick Allanore⁸, ¹Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, ²Heart Institute, University of PECS, Pecs, Hungary, ³Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴CHU Lille, Lille, France, ⁵Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Department of Dermatology, University of Cologne, Cologne, Germany, ⁷Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France
Background/Purpose: Heart involvement both of primary origin or secondary to lung disease is a key contributor to morbidity and mortality in systemic sclerosis (SSc). While…
Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting
IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Atsuma Nishiwaki¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Isamu Yokoe¹, Noboru Kitamura², Hidetake Shiraiwa¹, Takamasa Nozaki¹, Hirotake Inomata², Natsumi Ikumi⁴, Kaita Sugiyama¹, Yousuke Nagasawa¹ and Masami Takei⁵, ¹Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
Abstract Number: 1687 • 2014 ACR/ARHP Annual Meeting
Key Role of Cardiac Biomarkers in the Assessment of Systemic Sclerosis: Contribution of High Sensitivity Cardiac Troponin
Jerome Avouac¹, Christophe Meune², Camille Gobeaux³, Didier Borderie³, Guillaume Lefevre⁴, Andre Kahan⁵ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, Bobigny, France, ³Paris Descartes University, Biochemistry A department, Cochin Hospital, Paris, France, ⁴Clinical Chemistry and Hormonology Department, Tenon Hospital, paris, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France
Background/Purpose: Microangiopathy is a cardinal feature of systemic sclerosis (SSc), which plays a critical role in the development of primary myocardial involvement and pulmonary hypertension,…
Abstract Number: 957 • 2014 ACR/ARHP Annual Meeting
Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity?
Debora Russo¹, Carla G.S. Saad², Ana C.M. Ribeiro¹, Cláudia Goldeinstein-Schainberg², Percival D Sampaio-Barros², Celio R. Gonçalves², Eloisa Bonfá¹ and Julio C. B. Moraes², ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular risk with recent evidence that short-term inflammation control reduces its levels in ankylosing…
Abstract Number: 783 • 2013 ACR/ARHP Annual Meeting
Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death
Stefan Kleinert¹, Margret Breunig², Hans-Peter Tony³, Martin Feuchtenberger⁴, Marc Schmalzing⁵, Christian Kneitz⁶, Stefanie Lehmann⁷, Christiane Angermann^7,8, Georg Ertl⁸ and Stefan Störk⁷, ¹Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ²Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, ³Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁶Internal Medicine II, Hospital Südstadt, Rostock, Germany, ⁷Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, ⁸Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion…
Abstract Number: 694 • 2013 ACR/ARHP Annual Meeting
Peripheral Bone Marrow-Derived Endothelial Progenitor Cells and N-Terminal Probrain Natriuretic Peptide in Scleroderma Mexican Patients With and Without Diastolic Dysfunction: A Preliminary Report
Jesús Sepúlveda^1,2, Olga Vera-Lastra³, Maria Pilar Cruz-Dominguez⁴, Laura Montiel-Cervantes⁵, Joaquín Gómez-León⁶, Luis Robles-Espinoza⁷, Ramón Lozano-Morales⁷, Sergio Mendoza-Alvarez¹, Rubiraida Molina-Aguilar⁵, Gabriela Medina⁸, Jorge Vela-Ojeda⁹ and Luis J. Jara¹⁰, ¹Internal Medicine, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ²Unidad de Estudios de Posgrado, Universidad Nacional Autónoma de México, Mexico City, Mexico, ³Internal Medicine, MD, Mexico City, Mexico, ⁴Division of Research, Hospital de Especialidades Centro Medico Nacional La Raza., Mexico, DF, Mexico, ⁵Hematology Laboratory, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁶Cardiology Department, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁷Central Laboratory, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸CMN La Raza IMSS, Seris/Zachila s/n La Raza, Mexico City, Mexico, ⁹Instituto Mexicano del Seguro Social, Mexico City, Mexico, ¹⁰Research and Education, Hospital de Especialidades Centro Medico La Raza, México City, Mexico
Background/Purpose: Diastolic dysfunction (DD) in systemic sclerosis (SSc) is a marker of increased risk of death. The N-terminal pro-brain natriuretic peptide (NT-proBNP) is a neurohormone…
Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Lada Miller¹, Sandra Chartrand¹, Martial Koenig², Jean-Richard Goulet³, Eric Rich¹, Michal Abrahamowicz⁴, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁴Centre Universitaire de Santé McGill (CUSM), Montreal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…
Abstract Number: 533 • 2012 ACR/ARHP Annual Meeting
NT-Probnp and Inflammation in Active Ankylosing Spondylitis Receiving TNF Blockers: Is There a Link?
Julio C. B. Moraes¹, Ana C. M. Ribeiro², Carla G.S. Saad³, Alessandro C. Lianza⁴, Nadia E. Aikawa⁵, Clovis Artur Silva⁶ and Eloisa Bonfa⁷, ¹Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ⁴Radiology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, University of São Paulo, Sao Paulo, Brazil, ⁶Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁷Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Cardiovascular disease plays a central role in morbidity and mortality in rheumatic patients. N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular…
Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Inge A.M. van den Oever and Mike T. Nurmohamed, Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].